Your Health, We Care
Release date: 2025-04-18 10:32:52 Article From: Lucius Laos Recommended: 264
Focusing on the clinical value of finerenone, the medical community is conducting in-depth discussions.
The drug reduces the rate of protein excretion by selectively inhibiting mineralocorticoid receptors.
Data from the phase III clinical trial showed an average reduction of 31% in urine protein levels and a 29% slowdown in the decline of kidney function.
It is mainly for patients with type 2 diabetes who have chronic metabolic problems. The inclusion criteria of the study showed that the glomerular filtration rate of the subjects should be in the range of 25-75ml/min/1.73m² with microproteinuria.
The daily cost of medication is about $4.2, and the annual cost of treatment is about $1,500. It is important to note that actual expenditures may fluctuate depending on dose adjustments or adjuvant therapy.
Treatment decisions need to be made in conjunction with individualized medical needs.
Compared with spironolactone, the incidence of electrolyte abnormalities was reduced by 40%. Compared with eplerenone, it lowers blood pressure by 15%, but serum potassium levels need to be monitored regularly.
Dietary intervention delayed medication requirements in 24% of patients. 150 minutes of moderate-intensity exercise per week combined with a low-sodium diet improved urine protein by 18% in some cases.
Electrolytes are measured every two weeks at the beginning of treatment and monthly when they are stable. For special populations, it is recommended to start with half a dose and gradually adjust to the target dose.
Medical decisions should be based on a comprehensive assessment, with regular testing and dynamic adjustments constituting key elements of treatment success. Personalized solutions under the guidance of a professional team can maximize the desired treatment goals.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2622025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4832024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2672025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2772025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2582025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：3032025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2652025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2442025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
